Your browser doesn't support javascript.
loading
Potent, Gut-Restricted Inhibitors of Divalent Metal Transporter 1: Preclinical Efficacy against Iron Overload and Safety Evaluation.
Cutts, Alison; Chowdhury, Sultan; Ratkay, Laszlo G; Eyers, Maryanne; Young, Clint; Namdari, Rostam; Cadieux, Jay A; Chahal, Navjot; Grimwood, Michael; Zhang, Zaihui; Lin, Sophia; Tietjen, Ian; Xie, Zhiwei; Robinette, Lee; Sojo, Luis; Waldbrook, Matthew; Hayden, Michael; Mansour, Tarek; Pimstone, Simon; Goldberg, Y Paul; Webb, Michael; Cohen, Charles J.
  • Cutts A; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Chowdhury S; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Ratkay LG; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Eyers M; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Young C; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Namdari R; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Cadieux JA; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Chahal N; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Grimwood M; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Zhang Z; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Lin S; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Tietjen I; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Xie Z; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Robinette L; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Sojo L; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Waldbrook M; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Hayden M; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Mansour T; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Pimstone S; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Goldberg YP; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Webb M; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
  • Cohen CJ; Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada(A.C., S.C., L.G.R., M.E., C.Y., R.N., J.A.C., N.C., M.G., Z.Z., S.L., I.T., Z.X., L.R., L.S., M.W., M.H., T.M., S.P., Y.P.G., M.W., C.J.C.) and Division of General Internal Medicine, University of British Columbia, Vancouver, British Colu
J Pharmacol Exp Ther ; 386(1): 4-14, 2023 07.
Article en En | MEDLINE | ID: mdl-36958846
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sobrecarga de Hierro Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sobrecarga de Hierro Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article